Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30711330.
- Also identified by DOI 10.1016/j.eururo.2019.01.026.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Results from the ERA 223 trial of abiraterone combined with radium-223 among men with chemotherapy-naïve castration-resistant prostate cancer and bone metastases show no improvement in survival free from symptomatic skeletal events. We hypothesize that this finding might be attributable to bone loss induced by the concomitantly administered prednisone.
Medical subject headings
- Fractures, Bone
- Prostatic Neoplasms, Castration-Resistant
- Radium